Trial Profile

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rucaparib (Primary) ; Bevacizumab; Carboplatin
Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms MAMOC; MAMOC NOGGO-ov42

Most Recent Events

15 Nov 2024 Status changed from discontinued to completed.
04 Jan 2024 Status changed from active, no longer recruiting to discontinued, according to a European Clinical Trials Database record.
20 Nov 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com